These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 33969575)
1. Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma. Liu QQ; Liu YW; Xie YK; Zhang JH; Song CX; Wang JZ; Xie BH Cell Biol Int; 2021 Sep; 45(9):1906-1916. PubMed ID: 33969575 [TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-8 induces sorafenib resistance via binding with c-Rel to mediate NF-κB signaling in hepatocellular carcinoma. Liu HF; Xie YK; Zhong BY; Zhang JH; Song CX; Liu YW; Yang Y; Xie BH Cell Biol Int; 2022 Feb; 46(2):213-221. PubMed ID: 34719075 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway. Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705 [TBL] [Abstract][Full Text] [Related]
4. GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. Zhou Y; Zhao H; Ren R; Zhou M; Zhang J; Wu Z; Chen Y; Lei J; Chen Y; Yu Y; Li Y Theranostics; 2024; 14(9):3470-3485. PubMed ID: 38948063 [No Abstract] [Full Text] [Related]
5. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma. Wu J; Chai H; Li F; Ren Q; Gu Y Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976 [TBL] [Abstract][Full Text] [Related]
6. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734 [TBL] [Abstract][Full Text] [Related]
7. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012 [TBL] [Abstract][Full Text] [Related]
8. DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC. Liu W; Zhang F; Quan B; Yao F; Chen R; Ren Z; Dong L; Yin X Cell Mol Gastroenterol Hepatol; 2024; 18(4):101377. PubMed ID: 38969205 [TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma. Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472 [TBL] [Abstract][Full Text] [Related]
11. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1. Guo XL; Wang HB; Yong JK; Zhong J; Li QH Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839 [TBL] [Abstract][Full Text] [Related]
12. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700 [TBL] [Abstract][Full Text] [Related]
13. DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression. Li Z; Kim W; Utturkar S; Yan B; Lanman NA; Elzey BD; Kazemian M; Yeo Y; Andrisani O Cell Death Dis; 2024 Aug; 15(8):583. PubMed ID: 39122708 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma. Li H; Hu J; Qiu L; Wu Y; Zhong B; Ye R; Xie B Anticancer Drugs; 2024 Jan; 35(1):55-62. PubMed ID: 37823256 [TBL] [Abstract][Full Text] [Related]
16. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776 [TBL] [Abstract][Full Text] [Related]
17. The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma. Li Y; Li J; Chen H; Wang J; Jiang L; Tan X J Biochem Mol Toxicol; 2022 Sep; 36(9):e23119. PubMed ID: 35678308 [TBL] [Abstract][Full Text] [Related]
18. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma. Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410 [TBL] [Abstract][Full Text] [Related]
19. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis. Weng YS; Chiang IT; Tsai JJ; Liu YC; Hsu FT Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):719-732. PubMed ID: 36245124 [TBL] [Abstract][Full Text] [Related]
20. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]